JAK2 and acute lymphoblastic leukemia: Studies in CRLF2-re/JAK2-mutated ALL cell lines, engineered BaF/3 cells or primary ALL PDX cultured ex vivo showed very little activity of ruxolitinib at sub-micro molar concentrations used.